Meridian Bioscience Stock

Meridian Bioscience FCF/Debt

The Free Cash Flow to Debt Ratio of Meridian Bioscience (VIVO) as of Sep 11, 2026 is 294.98 %. In the previous year, Free Cash Flow to Debt Ratio was 80.92 % — a change of 264.53% (higher).

FCF/Debt

294.98 %

YoY

264.53%

Last updated:

Free Cash Flow to Debt Ratio of Meridian Bioscience is 2026 294.98 % . Free Cash Flow to Debt Ratio of Meridian Bioscience was 2025 80.92 % . It decreases by 264.53% higher compared to the previous year.

The Meridian Bioscience FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2016
56.88 USD
Jan 1, 2017
67.56 USD
Jan 1, 2018
60.92 USD
Jan 1, 2019
42.72 USD
Jan 1, 2020
64.94 USD
Jan 1, 2021
80.92 USD
Jan 1, 2022
294.98 USD
The Meridian Bioscience FCF/Debt history
YEARFCF/DebtYoY
294.98 %+264.53%
80.92 %+24.61%
64.94 %+52.03%
42.72 %-29.87%
60.92 %-9.84%
67.56 %+18.78%
56.88 %
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Free Cash Flow to Debt Ratio of Meridian Bioscience is 294.98 % in 2026.

Free Cash Flow to Debt Ratio of Meridian Bioscience changed from 80.92 % to 294.98 %, representing a 264.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Meridian Bioscience

All Key Metrics — Meridian Bioscience